GASTROESOPHAGEAL-JUNCTION CANCER
Clinical trials for GASTROESOPHAGEAL-JUNCTION CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL-JUNCTION CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL-JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New antibody TST001 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tests a new drug called TST001, an antibody that targets a protein (CLDN18.2) found on some cancer cells. It is being studied alone or with other treatments in about 150 people with advanced stomach, esophageal, or pancreatic cancers that have not responded…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug cocktail aims to stop esophageal cancer from coming back
Disease control OngoingThis study looks at whether a 1-year treatment with two drugs (Enhertu and nivolumab) can safely prevent cancer from returning in people with HER2-positive esophageal or stomach-junction cancer. Participants have already completed standard therapy (chemoradiation and surgery) but…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for advanced stomach cancer: targeted drug trial shows promise
Disease control OngoingThis study tests a new drug called AZD0901 in 33 adults with advanced stomach or gastroesophageal junction cancer that has spread or cannot be removed. Participants must have a specific protein (CLDN18.2) on their cancer cells and have already tried at least one prior treatment. …
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for stomach cancer: drug combo shows promise in early trial
Disease control OngoingThis study is testing a new drug called bemarituzumab combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 72 adul…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Engineered immune cells take on Hard-to-Treat digestive cancers
Disease control OngoingThis early-phase trial tests a new treatment called LB1908, which uses a patient's own immune cells (T-cells) engineered to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes adults with advanced stomach, gastroesophagea…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New antibody drug shows promise in fighting advanced cancers
Disease control OngoingThis study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that has spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New dual-immunotherapy combo tested in advanced cancers
Disease control OngoingThis early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 08, 2026 12:01 UTC